JBIO Jade Biosciences, Inc.
company
SEC Filings & Insider Trading Activity 2026

CIK: 1798749
Health Care
Pharmaceutical Preparations 24 filings
Russell 2000

Latest Jade Biosciences, Inc. (JBIO) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on March 6, 2026, a 10-Q quarterly report filed on November 14, 2025, an 8-K current report filed on April 22, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Jade Biosciences, Inc. (JBIO) (SEC CIK 1798749), with AI-powered section-by-section summaries updated daily.

10-Q: 14
8-K: 5
10-K: 5

Latest 2026 SEC Filing Dates

10-K Annual Report
Mar 6, 2026
10-Q Quarterly Report
Nov 14, 2025
8-K Current Report
Apr 22, 2026

AI 8-K Current Report Analysis
Recent 8-K Filings

Filed Mar 6, 2026
8-K
Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q4 and full-year 2025 financial results announced March 6, 2026
  • Actual figures in Exhibit 99.1 press release — key metrics not disclosed in this filing item

Recent 8-K Filings
Current Reports

AI-powered analysis of Jade Biosciences, Inc. (JBIO) 8-K current reports disclosing material events.

Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4

FormFiling DatePeriodAnalysisSEC
8-K
Apr 22, 2026
8-K
Apr 2, 2026
10-K
Mar 6, 2026Dec 31, 2025
8-K
Mar 6, 2026Analysis
8-K
Jan 5, 2026
8-K
Dec 15, 2025
10-Q
Nov 14, 2025Sep 30, 2025
10-Q
Aug 13, 2025Jun 30, 2025
10-Q
Apr 25, 2025Mar 31, 2025
10-K
Mar 27, 2025Dec 31, 2024
10-Q
Nov 12, 2024Sep 30, 2024
10-Q
Aug 12, 2024Jun 30, 2024
10-Q
May 13, 2024Mar 31, 2024
10-K
Mar 25, 2024Dec 31, 2023
10-Q
Nov 13, 2023Sep 30, 2023
10-Q
Aug 14, 2023Jun 30, 2023
10-Q
May 15, 2023Mar 31, 2023
10-K
Mar 29, 2023Dec 31, 2022
10-Q
Nov 14, 2022Sep 30, 2022
10-Q
Aug 15, 2022Jun 30, 2022
10-Q
May 16, 2022Mar 31, 2022
10-K
Mar 30, 2022Dec 31, 2021
10-Q
Nov 15, 2021Sep 30, 2021
10-Q
Aug 16, 2021Jun 30, 2021

Frequently Asked Questions

What are the latest JBIO SEC filings in 2026?

Jade Biosciences, Inc. (JBIO) has filed a 10-K annual report on March 6, 2026, a 10-Q quarterly report on November 14, 2025, an 8-K current report on April 22, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did JBIO file its most recent 10-K annual report?

Jade Biosciences, Inc. (JBIO) filed its most recent 10-K annual report on March 6, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view JBIO 10-Q quarterly reports?

Jade Biosciences, Inc. (JBIO)'s most recent 10-Q quarterly report was filed on November 14, 2025. SignalX displays every JBIO 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has JBIO filed recently?

Jade Biosciences, Inc. (JBIO)'s most recent 8-K was filed on April 22, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find JBIO insider trading activity (Form 4)?

SignalX aggregates every JBIO Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does JBIO file with the SEC?

Jade Biosciences, Inc. (JBIO) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new JBIO filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Jade Biosciences, Inc. (JBIO).

What is JBIO's SEC CIK number?

Jade Biosciences, Inc. (JBIO)'s SEC CIK (Central Index Key) number is 1798749. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1798749 to look up all JBIO filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find JBIO return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Jade Biosciences, Inc. (JBIO) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.

Stay on top of Jade Biosciences, Inc. SEC filings

Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 24+ filings.